WO1996041606A3 - Compositions pharmaceutiques ameliorees utilisees pour la therapie genique - Google Patents

Compositions pharmaceutiques ameliorees utilisees pour la therapie genique Download PDF

Info

Publication number
WO1996041606A3
WO1996041606A3 PCT/GB1996/001396 GB9601396W WO9641606A3 WO 1996041606 A3 WO1996041606 A3 WO 1996041606A3 GB 9601396 W GB9601396 W GB 9601396W WO 9641606 A3 WO9641606 A3 WO 9641606A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
pharmaceutical compositions
gene therapy
improved pharmaceutical
peptides
Prior art date
Application number
PCT/GB1996/001396
Other languages
English (en)
Other versions
WO1996041606A2 (fr
Inventor
David Robert Thatcher
Roger Kingdon Craig
Paula Elizabeth Wilks
Vincent Trevor Cunliffe
John Hamilton Welsh
Original Assignee
Therexsys Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9513399.7A external-priority patent/GB9513399D0/en
Priority claimed from GBGB9519304.1A external-priority patent/GB9519304D0/en
Priority claimed from GBGB9525955.2A external-priority patent/GB9525955D0/en
Application filed by Therexsys Ltd filed Critical Therexsys Ltd
Priority to EP96917590A priority Critical patent/EP0831922A2/fr
Priority to AU60114/96A priority patent/AU6011496A/en
Priority to JP50279197A priority patent/JP2002514892A/ja
Publication of WO1996041606A2 publication Critical patent/WO1996041606A2/fr
Publication of WO1996041606A3 publication Critical patent/WO1996041606A3/fr

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nanotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Cette invention est fondée sur la découverte d'une particule de synthèse du type virus contenant une pluralité de peptides capables de condenser de l'acide nucléique et de l'acide nucléique condensé. La pluralité de peptides présente un faible indice de polydispersion et chaque peptide est un hétéropeptide. L'acide nucléique peut coder des séquences possédant un intérêt thérapeutique. La particule de synthèse du type virus s'assemble elle-mème et peut être conçue de manière à pouvoir cibler une cellule ou un type de tissu particulier et apporter l'acide nucléique devant être incorporé dans les séquences chromosomiques ou extrachromosomiques des cellules ou des tissus ciblés.
PCT/GB1996/001396 1995-06-08 1996-06-10 Compositions pharmaceutiques ameliorees utilisees pour la therapie genique WO1996041606A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP96917590A EP0831922A2 (fr) 1995-06-08 1996-06-10 Compositions pharmaceutiques ameliorees utilisees pour la therapie genique
AU60114/96A AU6011496A (en) 1995-06-08 1996-06-10 Improved pharmaceutical compositions for gene therapy
JP50279197A JP2002514892A (ja) 1995-06-08 1996-06-10 遺伝子治療における合成ウイルス様粒子の使用

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US12495P 1995-06-08 1995-06-08
GB9513399.7 1995-06-30
GBGB9513399.7A GB9513399D0 (en) 1995-06-30 1995-06-30 Improved pharmaceutical compositions for gene therapy
GBGB9519304.1A GB9519304D0 (en) 1995-09-21 1995-09-21 Improved pharmaceutical compositions for gene therapy
GB9519304.1 1995-09-21
US428595P 1995-09-25 1995-09-25
US895295P 1995-12-19 1995-12-19
GBGB9525955.2A GB9525955D0 (en) 1995-12-19 1995-12-19 Improved pharmaceutical compositions
US1153196P 1996-02-12 1996-02-12
US66023196A 1996-06-07 1996-06-07
US60/004,285 1996-06-07
US08/660,231 1996-06-07
US60/011,531 1996-06-07
US60/000,124 1996-06-07

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US86128397A Continuation-In-Part 1996-02-12 1997-05-21

Publications (2)

Publication Number Publication Date
WO1996041606A2 WO1996041606A2 (fr) 1996-12-27
WO1996041606A3 true WO1996041606A3 (fr) 1997-05-22

Family

ID=27571323

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1996/001396 WO1996041606A2 (fr) 1995-06-08 1996-06-10 Compositions pharmaceutiques ameliorees utilisees pour la therapie genique

Country Status (4)

Country Link
EP (1) EP0831922A2 (fr)
JP (1) JP2002514892A (fr)
AU (1) AU6011496A (fr)
WO (1) WO1996041606A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9364519B2 (en) 2011-09-01 2016-06-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US9408893B2 (en) 2011-08-29 2016-08-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479464B1 (en) 1997-05-21 2002-11-12 Cobra Therapeutics Limited Compositions and methods for highly efficient transfection
WO1997028818A1 (fr) * 1996-02-12 1997-08-14 Cobra Therapeutics Limited Nouveaux procedes de vaccination et vaccins associes comprenant un acide nucleique codant un premier epitope, ainsi qu'un peptide contenant un second epitope
US6689757B1 (en) 1996-02-12 2004-02-10 M.L. Laboratories Plc Methods for vaccination and vaccines therefor
US8007784B1 (en) 1996-06-27 2011-08-30 Albany Medical College Antigenic modulation of cells
DE69836746D1 (de) * 1997-02-12 2007-02-08 Innovata Plc Nottingham Zusammensetzungen sowie verfahren zur hocheffizienten transfektion
US5925628A (en) * 1997-03-31 1999-07-20 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5912239A (en) * 1997-04-04 1999-06-15 Genzyme Corporation Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules
US5948925A (en) * 1997-05-06 1999-09-07 Genzyme Corporation Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
US5952516A (en) * 1997-05-08 1999-09-14 Genzyme Corporation Cationic amphiphiles containing multiplesteroid lipophilic groups
US5942634A (en) * 1997-05-09 1999-08-24 Genzyme Corporation Cationic amphiphiles for cell transfections
AU7987898A (en) * 1997-06-26 1999-01-19 Albany Medical College Antigenic modulation of viral particules
WO1999040771A2 (fr) 1998-02-13 1999-08-19 Selective Genetics, Inc. Procedes de melange de flux en parallele, appareils de preparation de vecteurs pour la therapie genique et compositions preparees de cette maniere
WO1999042091A2 (fr) 1998-02-19 1999-08-26 Massachusetts Institute Of Technology Compositions d'apport dans des cellules
CA2333852C (fr) 1998-07-21 2007-05-29 Cobra Therapeutics Limited Polynucleotide comportant un element d'ouverture de la chromatine ubiquiste (ucoe)
AU5590999A (en) * 1998-09-01 2000-03-21 Trustees Of The University Of Pennsylvania, The Peptide scaffolds for transfer of molecules into eukaryotic cells
US6927278B1 (en) 1998-09-01 2005-08-09 Trustees Of The University Of Pennsylvania Peptide scaffolds for transfer of molecules into eukaryotic cells
WO2000063409A1 (fr) * 1999-04-21 2000-10-26 Massachusetts Institute Of Technology Agents endosomolytiques et systemes de liberation dans des cellules
WO2000075162A1 (fr) * 1999-06-07 2000-12-14 Mirus Corporation Compose contenant une liaison instable de bisulfure
WO2000075164A1 (fr) * 1999-06-07 2000-12-14 Mirus Corporation Compositions et methodes de diffusion de medicaments au moyen de molecules sensibles au ph
GB9918670D0 (en) 1999-08-06 1999-10-13 Celltech Therapeutics Ltd Biological product
JP2004500097A (ja) 2000-03-02 2004-01-08 エムエル　ラボラトリーズ　ピーエルシー Ｔｃｆ応答性エレメント
EP1272221A2 (fr) * 2000-04-12 2003-01-08 Implyx Ltd. Conjugues de peptides utilises pour l'apport de medicament
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
JP5102630B2 (ja) * 2005-11-24 2012-12-19 ジェノミディア株式会社 改変パラミクソウイルスおよびその作製方法
CA2740685C (fr) 2008-10-17 2018-09-11 Sanofi-Aventis Deutschland Gmbh Combinaison d'une insuline et d'un agoniste de glp-1
JP5973918B2 (ja) 2009-11-13 2016-08-23 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｇｌｐ−１アゴニスト及びメチオニンを含む薬学的組成物
AU2010317995B2 (en) 2009-11-13 2014-04-17 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
EP3689381A1 (fr) 2010-06-22 2020-08-05 Onxeo Système d'administration in vivo optimisé doté d'agents endosomolytiques pour conjugués d'acides nucléiques
JP6199186B2 (ja) 2010-08-30 2017-09-20 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病の治療用の医薬の製造のためのａｖｅ００１０の使用
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
HRP20230470T1 (hr) 2014-12-12 2023-07-21 Sanofi-Aventis Deutschland Gmbh Formulacija fiksnog omjera inzulin glargin/liksisenatid
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
CN108138177B9 (zh) 2015-07-23 2021-08-13 法国居里学院 Dbait分子与PARP抑制剂的组合用于治疗癌症的用途
JP6661797B2 (ja) * 2016-11-22 2020-03-11 株式会社東芝 核酸凝縮ペプチド、核酸凝縮ペプチドセット、核酸送達キャリア、核酸送達方法、細胞作製方法、細胞検出方法及びキット
AU2018286475A1 (en) 2017-06-13 2019-12-19 Monash University Non-viral gene delivery agent comprising lipopeptide (LP) compounds
MX2021005313A (es) * 2018-11-08 2021-10-13 Summation Bio Inc Proteínas de núcleo de mininucleosoma y uso en entrega de ácido nucleico.

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0544292A2 (fr) * 1991-11-27 1993-06-02 Roche Diagnostics GmbH Méthode d'introduction d'acides nucléiques dans des cellules
WO1993019768A1 (fr) * 1992-04-03 1993-10-14 The Regents Of The University Of California Systeme de livraison d'un polynucleotide a assemblage autonome
DE4412629A1 (de) * 1993-04-14 1995-01-26 Boehringer Mannheim Gmbh Nukleinsäure-transferpeptide und deren Verwendung zur Einschleusung von Nukleinsäuren in eukaryontische Zellen
WO1995006056A1 (fr) * 1993-08-20 1995-03-02 University Of Medicine & Dentistry Of New Jersey Conjugues polycationiques polymeres-oligonucleotides a pont et procedes de preparation
WO1995021931A1 (fr) * 1994-02-08 1995-08-17 Rhone-Poulenc Rorer S.A. Composition contenant des acides nucleiques, preparation et utilisations
WO1996019241A1 (fr) * 1994-12-19 1996-06-27 Medical Research Council Complexes de ciblage et leur utilisation
WO1996025508A1 (fr) * 1995-02-17 1996-08-22 Rhone-Poulenc Rorer S.A. Compositions contenant des acides nucleiques, preparation et utilisation

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0544292A2 (fr) * 1991-11-27 1993-06-02 Roche Diagnostics GmbH Méthode d'introduction d'acides nucléiques dans des cellules
WO1993019768A1 (fr) * 1992-04-03 1993-10-14 The Regents Of The University Of California Systeme de livraison d'un polynucleotide a assemblage autonome
DE4412629A1 (de) * 1993-04-14 1995-01-26 Boehringer Mannheim Gmbh Nukleinsäure-transferpeptide und deren Verwendung zur Einschleusung von Nukleinsäuren in eukaryontische Zellen
WO1995006056A1 (fr) * 1993-08-20 1995-03-02 University Of Medicine & Dentistry Of New Jersey Conjugues polycationiques polymeres-oligonucleotides a pont et procedes de preparation
WO1995021931A1 (fr) * 1994-02-08 1995-08-17 Rhone-Poulenc Rorer S.A. Composition contenant des acides nucleiques, preparation et utilisations
WO1996019241A1 (fr) * 1994-12-19 1996-06-27 Medical Research Council Complexes de ciblage et leur utilisation
WO1996025508A1 (fr) * 1995-02-17 1996-08-22 Rhone-Poulenc Rorer S.A. Compositions contenant des acides nucleiques, preparation et utilisation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LEGENDRE, J.-Y. ET AL.: "Cyclic amphipathic peptide-DNA complexes mediate high-efficiency transfection of adherent mammalian cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 90, February 1993 (1993-02-01), WASHINGTON US, pages 893 - 897, XP002023679 *
ROKEACH LA ET AL: "Molecular cloning of a cDNA encoding the human Sm-D autoantigen.", PROC NATL ACAD SCI U S A, JUL 1988, VOL. 85, NO. 13, PAGE(S) 4832-6, XP002023680 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9408893B2 (en) 2011-08-29 2016-08-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
US9364519B2 (en) 2011-09-01 2016-06-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for use in the treatment of a neurodegenerative disease

Also Published As

Publication number Publication date
EP0831922A2 (fr) 1998-04-01
WO1996041606A2 (fr) 1996-12-27
JP2002514892A (ja) 2002-05-21
AU6011496A (en) 1997-01-09

Similar Documents

Publication Publication Date Title
WO1996041606A3 (fr) Compositions pharmaceutiques ameliorees utilisees pour la therapie genique
Arar et al. Synthesis and Antiviral Activity of Peptide-Oligonucleotide Conjugates Prepared by Using N. Alpha.-(Bromoacetyl) Peptides
CA2370289A1 (fr) Peptides inhibiteurs de l'exocytose neuronale, compositions cosmetiques et pharmaceutiques les contenant
WO2000003683A3 (fr) Complexes d'acides nucleiques encapsules dans des liposomes
IL112372A (en) Non-viral vector for the delivery of genetic information to cells
EP1188768A3 (fr) Peptides antagonistes de LHRH
AU4526193A (en) Binding competent oligomers containing 2', 5' linkages
AU2790292A (en) Viral recombinant vectors for expression in muscle cells
ATE238038T1 (de) Liposomale formulierungen von mitoxantron
CA2257133A1 (fr) Variantes hyperactives de la desoxyribonuclease i humaine
CA2333145A1 (fr) Dispositif de liberation de medicaments comprenant un peptide a homeoboite et un composant de liberation de nature non peptidique et non nucleotidique
NZ289899A (en) Peptide which binds to the p53 suppressor site of the MDM2 oncogene
WO2003068144A3 (fr) Agents cytotoxiques supportant une fraction reactive de polyethyleneglycol, conjugues cytotoxiques comprenant des groupes de liaison de polyethyleneglycol et leurs procedes de fabrication et d'utilisation
CA2242035A1 (fr) Compositions utiles pour le transfert de substances therapeutiques actives dans une cellule-cible, et leur utilisation en therapie genique
WO2002064766A3 (fr) Genes reagissant a bax, destines a l'identification des cibles de medicaments dans la levure et les champignons
EP0349342A3 (fr) Polypeptides ayant une activité dispersante de cellules
GB9722320D0 (en) Human cell cycle checkpoint proteins
ATE215099T1 (de) Kationische polymere, diese kationische polymere enthaltende komplexe und wenigstens eine negative ladung enthaltende therapeutisch wirksame mittel, insbesondere nukleinsäuren und ihre verwendung in gentherapie
NZ331063A (en) Isolated nucleotide sequences encoding for mature LS- DNase which is resistant to actin inhibition
CA2155017A1 (fr) Fonction proteinique vpr et activite de celle-ci
NZ504445A (en) Nucleic acid sequences of genes of the high mobility group proteins and their use in treating tumours, vascular disorders and as a contraceptive
ATE391186T1 (de) Gezielte verabreichung von kuenstlichen genen
EP1020529A3 (fr) Vecteurs d'apport de gènes munis d'un tropisme pour les cellules des muscles lisses et/ou les cellules endothéliales
WO2001057069A3 (fr) Peptides capables de ciblage
PT1294874E (pt) Variantes de cd154 e as suas utilizacoes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

WPC Withdrawal of priority claims after completion of the technical preparations for international publication

Free format text: GB US

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2224146

Country of ref document: CA

Ref country code: CA

Ref document number: 2224146

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996917590

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996917590

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1996917590

Country of ref document: EP